Onychomycosis-Tinea-Unguium-Drug-Sales-Market-Report-2017
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong><br />
<strong>Sales</strong> <strong>Market</strong> <strong>Report</strong> <strong>2017</strong><br />
No of Pages – 142<br />
Publishing Date - March 24, <strong>2017</strong><br />
Browse detailed TOC, Tables, Figures, Charts in Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>)<br />
<strong>Drug</strong> <strong>Sales</strong> <strong>Market</strong> <strong>Report</strong> <strong>2017</strong> at- https://www.absolutereports.com/10692417<br />
This report studies the <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> market status and outlook of global<br />
and major regions, from angles of players, regions, product types and end industries; this report<br />
analyzes the top players in global and major regions, and splits the <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>)<br />
<strong>Drug</strong> market by product type and applications/end industries.<br />
In the last several years, global market of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> change huge. In<br />
2016, global revenue of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> is nearly 2591.81 M USD. And the<br />
global growth rate is at 5.11% from 2012 to 2016.<br />
The major players in global market include<br />
Johnson & Johnson<br />
GSK<br />
Novartis<br />
Pfizer<br />
Valeant Pharma<br />
Kaken Pharmaceutical<br />
Galderma<br />
Xiuzheng Pharmaceutical<br />
Letai<br />
Qilu Pharmaceutical
Geographically, this report is segmented into several key regions, with revenue, market share (%)<br />
and growth Rate (%) of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> in these regions, from 2012 to 2022<br />
(forecast), covering<br />
USA<br />
China<br />
Europe<br />
Japan<br />
On the basis of product, the <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> market is primarily split into<br />
Oral<br />
External<br />
On the basis on the end users/applications, this report covers<br />
Age under 18<br />
Age 18-50<br />
Age above 50<br />
Ask for Discount at – https://www.absolutereports.com/enquiry/request-discount/10692417<br />
Table of Contents<br />
1 <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Market</strong> Overview 1<br />
1.1 Product Overview and Scope of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> 1
1.2 Classification of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> by Product Category 2<br />
1.2.1 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> by Types 2<br />
1.2.2 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Sales</strong> <strong>Market</strong> Share (%) by Types in 2016 2<br />
1.2.3 Oral 3<br />
1.2.4 External 3<br />
1.3 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Market</strong> by Applications/End Users 4<br />
1.3.1 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Market</strong> by Applications/End Users 4<br />
1.3.2 Age under 18 5<br />
1.3.3 Age 18-50 5<br />
1.3.4 Age above 50 6<br />
1.4 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Market</strong> by Regions 7<br />
1.4.1 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Status and Prospect (2012-2022) 7<br />
1.4.2 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Status and Prospect (2012-2022) 8<br />
1.4.3 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Status and Prospect (2012-2022) 9<br />
1.4.4 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Status and Prospect (2012-2022) 10<br />
1.5 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue and Growth Rate (2012-2022) 11<br />
2 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Competition by Players, Type and Application 12<br />
2.1 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Market</strong> Competition by Players 12<br />
2.2 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Sales</strong> and Revenue by Type 14<br />
2.3 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Sales</strong> and Revenue by Regions 17<br />
2.4 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Sales</strong> by Application 20<br />
3 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> (<strong>Sales</strong>, Revenue and Price) 23<br />
3.1 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (2012-<strong>2017</strong>) 23<br />
3.2 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Players 23
3.3 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by Type<br />
25<br />
3.4 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Applications 26<br />
4 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> (<strong>Sales</strong>, Revenue and Price) 28<br />
4.1 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Sales</strong> and Revenue (2012-<strong>2017</strong>) 28<br />
4.2 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Players 28<br />
4.3 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by Type<br />
30<br />
4.4 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by 32<br />
5 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> (<strong>Sales</strong>, Revenue and Price) 34<br />
5.1 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and Value (2012-<strong>2017</strong>) 34<br />
5.2 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Players 35<br />
5.3 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Type 37<br />
5.4 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Applications 38<br />
6 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> (<strong>Sales</strong>, Revenue and Price) 41<br />
6.1 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and Value (2012-<strong>2017</strong>) 41<br />
6.2 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by<br />
Players 41<br />
6.3 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue (M USD)and <strong>Market</strong> Share (%) by Type<br />
43<br />
6.4 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Sales</strong> and <strong>Market</strong> Share (%) by Applications 45<br />
7 Analysis of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Industry Key Manufacturers 47<br />
7.1 Johnson & Johnson 47<br />
7.1.1 Company Profile 47<br />
7.1.2 Product Information 48
7.1.3 Revenue, Cost, Gross, and Gross Margin 48<br />
7.2 GSK 50<br />
7.2.1 Company Profile 50<br />
7.2.2 Product Information 51<br />
7.2.3 Revenue, Cost, Gross, and Gross Margin 51<br />
7.3 Novartis 53<br />
7.3.1 Company Profile 53<br />
7.3.2 Product Information 54<br />
7.3.3 Revenue, Cost, Gross, and Gross Margin 54<br />
7.4 Pfizer 56<br />
7.4.1 Company Profile 56<br />
7.4.2 Product Information 57<br />
7.4.3 Revenue, Cost, Gross, and Gross Margin 57<br />
7.5 Valeant Pharma 59<br />
7.5.1 Company Profile 59<br />
7.5.2 Product Information 60<br />
7.5.3 Revenue, Cost, Gross, and Gross Margin 60<br />
7.6 Kaken Pharmaceutical 62<br />
7.6.1 Company Profile 62<br />
7.6.2 Product Information 63<br />
7.6.3 Revenue, Cost, Gross, and Gross Margin 63<br />
7.7 Galderma 65<br />
7.7.1 Company Profile 65<br />
7.7.2 Product Information 66<br />
7.7.3 Revenue, Cost, Gross, and Gross Margin 66
7.8 Xiuzheng Pharmaceutical 68<br />
7.7.1 Company Profile 68<br />
7.7.2 Product Information 69<br />
7.7.3 Revenue, Cost, Gross, and Gross Margin 70<br />
7.9 Letai 71<br />
7.9.1 Company Profile 71<br />
7.9.2 Product Information 72<br />
7.9.3 Revenue, Cost, Gross, and Gross Margin 72<br />
7.10 Qilu Pharmaceutical 74<br />
7.10.1 Company Profile 74<br />
7.10.2 Product Information 75<br />
7.10.3 Revenue, Cost, Gross, and Gross Margin 75<br />
8 <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Manufacturing Cost Analysis 77<br />
8.1 <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> R&D Cost Analysis 77<br />
8.1.1Clinical Phase Costs 78<br />
8.1.2 Capitalized Costs 79<br />
8.2 Proportion of Manufacturing Cost Structure 80<br />
8.2.1 Raw Materials 80<br />
8.2.2 Labor Cost 81<br />
8.2.3 Manufacturing Expenses 86<br />
8.3 Manufacturing Process Analysis of <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> 87<br />
9 Industrial Chain, Sourcing Strategy and Downstream Buyers 88<br />
9.1 <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Industrial Chain Analysis 88<br />
9.2 Upstream Raw Materials Sourcing 89<br />
9.3 Downstream Buyers 89
10 <strong>Market</strong>ing Strategy Analysis, Distributors/Traders 91<br />
10.1 <strong>Market</strong>ing Channel 91<br />
10.2 <strong>Market</strong> Positioning 92<br />
10.2.1 <strong>Market</strong> Positioning 92<br />
10.2.2 Brand Strategy 93<br />
10.2.2.1 Introducing pharmaceutical branding strategies 93<br />
10.2.2.2 Building pharmaceutical brands 94<br />
10.2.2.3 Communicating pharmaceutical brands 94<br />
10.2.2.4 Alternative brand models 95<br />
10.2.2.5 The future of pharmaceutical branding 95<br />
10.3 Distributors/Traders List 96<br />
11 <strong>Market</strong> Effect Factors Analysis 98<br />
11.1 Technology 98<br />
11.1.1 Treatment 98<br />
11.1.2 Technology Progress in Related Industry 98<br />
11.2 Consumer Needs/Customer Preference Change 100<br />
11.3 Economic/Political Environmental Change 100<br />
12 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> <strong>Market</strong> Forecast (<strong>2017</strong>-2022) 109<br />
12.1 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) Revenue Forecast (<strong>2017</strong>-2022) 109<br />
12.2 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue and Growth Rate Forecast by Regions<br />
(<strong>2017</strong>-2022) 110<br />
12.2.1 USA <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue and Growth Rate Forecast (<strong>2017</strong>-2022)<br />
112<br />
12.2.2 Europe <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue and Growth Rate Forecast<br />
(<strong>2017</strong>-2022) 113<br />
12.2.3 China <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue and Growth Rate Forecast<br />
(<strong>2017</strong>-2022) 114
12.2.4 Japan <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue and Growth Rate Forecast<br />
(<strong>2017</strong>-2022) 115<br />
12.3 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Revenue Forecast by Type (<strong>2017</strong>-2022) 115<br />
12.4 Global <strong>Onychomycosis</strong> (<strong>Tinea</strong> <strong>Unguium</strong>) <strong>Drug</strong> Forecast by Application (<strong>2017</strong>-2022) 117<br />
13 Research Findings and Conclusion 119<br />
14 Appendix 120<br />
Author List 120<br />
Methodology/Research Approach 121<br />
Research Programs/Design 121<br />
<strong>Market</strong> Size Estimation 122<br />
1.3 <strong>Market</strong> Breakdown and Data Triangulation 124<br />
Data Source 125<br />
Secondary Sources 125<br />
Primary Sources 126<br />
Disclaimer 127<br />
<strong>Report</strong> Details –<br />
Date of Publishing - March 24, <strong>2017</strong><br />
No of Pages – 142<br />
Single User PDF License – $4000<br />
Corporate License – $8000<br />
Buy Now - https://www.absolutereports.com/purchase/10692417<br />
About Absolute <strong>Report</strong>: Absolute <strong>Report</strong>s is an upscale platform to help key personnel in the<br />
business world in strategizing and taking visionary decisions based on facts and figures derived from<br />
in depth market research. We are one of the top report resellers in the market, dedicated towards<br />
bringing you an ingenious concoction of data parameters.<br />
Contact–<br />
Mr. Ameya Pingaley<br />
Absolute <strong>Report</strong>s
Powered by TCPDF (www.tcpdf.org)<br />
Powered by TCPDF (www.tcpdf.org)<br />
+1-408 520 9750<br />
Email – sales@absolutereports.com<br />
https://www.absolutereports.com/
Change language